JP Morgan Maintains Overweight on Xenon Pharmaceuticals, Raises Price Target to $82
Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. XENE | 0.00 |
JP Morgan analyst Tessa Romero maintains Xenon Pharmaceuticals (NASDAQ:
XENE) with a Overweight and raises the price target from $80 to $82.